blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3489222

EP3489222 - SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  26.03.2021
Database last updated on 05.10.2024
FormerRequest for examination was made
Status updated on  05.12.2019
FormerThe application has been published
Status updated on  26.04.2019
Most recent event   Tooltip14.11.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 Wedel / DE
[2019/22]
Inventor(s)01 / MENSONIDES-HARSEMA, Marguérite M.
1819 Latexo Drive
Houston, TX 77018 / US
02 / BIALLECK, Sebastian
medac GmbH
Theaterstr. 6
22880 Wedel / DE
 [2019/22]
Representative(s)Prinz & Partner mbB
Patent- und Rechtsanwälte
Leipziger Platz 15
10117 Berlin / DE
[N/P]
Former [2019/22]Feldmann, Ute
Patentanwaltskanzlei Feldmann
Leipziger Platz 15
10117 Berlin / DE
Application number, filing date17203275.723.11.2017
[2019/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3489222
Date:29.05.2019
Language:EN
[2019/22]
Search report(s)(Supplementary) European search report - dispatched on:EP30.11.2018
ClassificationIPC:C07D213/76, A61K31/4402, A61P29/00
[2019/22]
CPC:
C07D213/76 (EP,US); A61K31/4402 (US); A61K45/06 (US);
A61K9/0031 (US); A61K9/0053 (US); C07B2200/13 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/01]
Former [2019/22]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:SULFASALAZINESALZE, HERSTELLUNGSVERFAHREN UND VERWENDUNGEN[2019/22]
English:SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES[2019/22]
French:SELS DE SULFASALAZINE, PROCÉDÉS DE PRODUCTION ET UTILISATIONS[2019/22]
Examination procedure25.11.2019Amendment by applicant (claims and/or description)
25.11.2019Examination requested  [2020/01]
25.11.2019Date on which the examining division has become responsible
29.03.2021Despatch of a communication from the examining division (Time limit: M04)
03.08.2021Reply to a communication from the examining division
13.09.2022Despatch of a communication from the examining division (Time limit: M04)
18.01.2023Reply to a communication from the examining division
Fees paidRenewal fee
25.11.2019Renewal fee patent year 03
02.11.2020Renewal fee patent year 04
24.11.2021Renewal fee patent year 05
23.11.2022Renewal fee patent year 06
14.11.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XAI]GB1166684  (PHARMACIA AB [SE]) [X] 9 * example 1 * [A] 10-15 [I] 1-3,6,7;
 [XAI]CN106279008  (ZHEJIANG JIUZHOU PHARM CO LTD) [X] 9 * example 9 * [A] 10-15 [I] 1,2,4,7,8;
 [XA]  - LINDBERG ED - CLARY DAVID, "ESCA applied to liquids. ESCA spectra from molecular ions in solution", CHEMICAL PHYSICS LETTERS, ELSEVIER BV, NL, vol. 39, no. 1, (19760401), pages 8 - 10, URL: http://api.elsevier.com/content/article/PII:0009261476851834?httpAccept=text/plain, XP009503440 [X] 9 * figure 1 * [A] 10-15

DOI:   http://dx.doi.org/10.1016/0009-2614(76)85183-4
by applicantGB564990
 US2396145
 GB1166684
 WO9722596
 WO9730035
 WO9732856
 WO9813354
 WO9902166
 WO0001389
 WO0040529
 WO0041669
 WO0144239
 WO0192224
 WO0204434
 WO0208213
    - MATASIC R; DIETZ AB; VUK-PAVLOVIC S., "Maturation of human dendritic cells as sulfasalazine target", Croat Med J, (20010800), vol. 42, no. 4, pages 440 - 5, XP009027785
    - P GADANGI; M LONGAKER; D NAIME; R I LEVIN; P A RECHT; M C MONTESINOS; M T BUCKLEY; G CARLIN; B N CRONSTEIN, "The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites", J Immunol, (19960301), vol. 156, no. 5, pages 1937 - 1941
    - COUTO D1; RIBEIRO D; FREITAS M; GOMES A; LIMA JL; FERNANDES E., "Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine", Redox Rep., (20100000), vol. 15, no. 6, pages 259 - 67
    - NYGARD, B.; OLOFSSON, J.; SANDBERG, M., "Some physicochemical properties of salicylazosulphapyridine, including its solubility, protolytic constants and general spectrochemical and Polarographic behavior", Acta Pharmaceutica Suecica, (19660000), vol. 3, pages 313 - 342
    - GG MOHAMED et al., "Structural and Thermal Characterization of Cerium, Thorium and Uranyl Complexes of Sulfasalazine", Spectrochim Acta A Mol Biomol Spectrosc, (20050613), vol. 62, no. 4-5, doi:doi:10.1016/j.saa.2005.04.006, pages 1095 - 1101, XP005174792

DOI:   http://dx.doi.org/10.1016/j.saa.2005.04.006
    - ARIK DAHAN; GORDON L. AMIDON, "Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting", American Journal of Physiology - Gastrointestinal and Liver Physiology, (20090721), vol. 297, no. 2, pages G371 - G377
    - LIANG E1; CHESSIC K; YAZDANIAN M., "Evaluation of an accelerated Caco-2 cell permeability model.", J Pharm Sci., (20000300), vol. 89, no. 3, doi:doi:10.1002/(SICI)1520-6017(200003)89:3<336::AID-JPS5>3.0.CO;2-M, pages 336 - 45, XP002376235

DOI:   http://dx.doi.org/10.1002/(SICI)1520-6017(200003)89:3<336::AID-JPS5>3.0.CO;2-M
    - "United States Pharmacopeia Convention. X-Ray Diffraction, General Test <941 >", United States Pharmacopeial Convention, United States Pharmacopeia, (20020000), pages 2088 - 2089
    - "United States Pharmacopeia Convention. X-Ray Diffraction, General Test <941 >", United States Pharmacopeial Convention, United States Pharmacopeia, vol. 2002, pages 2088 - 2089
    - ZAMEK-GLISZCZYNSKI MJ et al., "Characterization of SAGE Mdr1 a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carbox-ydichloroflurorescein pharmacokinetics", Drug Metab Dispos, (20120000), vol. 40, page 1825
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.